The American College of Clinical Pharmacy (ACCP) 2011 publication “Tenets for Developing Quality Measures for Ambulatory Clinical Pharmacy Services” describes comprehensive, accountable, feasible, scientifically sound, and usable quality metrics for ambulatory care (AC) practice. ACCP endorsed the definition of comprehensive medication management (CMM) in 2014 and has since advocated consistent implementation of CMM in patient‐centered, team‐based care. Given the decade of changes and advances in AC practice since the 2011 publication, the 2020 ACCP Publications Committee has developed the present white paper to update quality metrics and provide performance indicators with proposed guidance for CMM in AC practice.

Patients moving between health care settings or providers are at increased risk of complications, including unplanned hospital readmissions and medication errors. Several actions must occur in concert with members of the health care team and across settings to ensure coordinated and continuous care for patients undergoing these transitions of care (TOC). Clinical pharmacists support patients during care transitions by providing interventions and services designed to improve medication outcomes. Clinical pharmacists and team members who support clinical pharmacist activities (eg, pharmacy students, technicians, and residents) are located throughout the care continuum, from acute care to care in the community, with each contributing to improved TOC outcomes. This article provides information on evidence of high‐impact clinical pharmacist TOC practices to serve as a practical guide for practitioners interested in starting or improving TOC activities. This article also addresses current and emerging best practices and offers suggestions for improving clinical pharmacist involvement in care transition activities.

The use of technology to deliver remote clinical pharmacy services can help broaden the patient reach and improve health-related outcomes, especially for individuals residing in rural locations. However, it can also promulgate health disparities and inequities, hindering access to care for vulnerable patient populations such as those with a lower socioeconomic or literacy background. This dichotomy of effect requires a thorough examination to create solutions that eliminate inequities. The 2021 American College of Clinical Pharmacy Public and Professional Relations Committee has developed this white paper to examine the potential impact of remote delivery of clinical pharmacy services on health disparities and access to care and proposes solutions and calls to action for clinical pharmacists to address these areas.

Background: Recent studies suggest that statins are underprescribed in patients living with HIV (PLWH) at risk for atherosclerotic cardiovascular disease (ASCVD), but none have assessed if eligible patients receive the correct statin and intensity compared to uninfected controls. Objectives: The primary objective was to determine whether statin-eligible PLWH are less likely to receive appropriate statin therapy compared to patients without HIV. Methods: This retrospective study evaluated statin eligibility and prescribing among patients in both an HIV and internal medicine clinic at an urban, academic medical center from June-September 2018 using the American College of Cardiology/American Heart Association guideline on treating blood cholesterol to reduce ASCVD risk. Patients were assessed for eligibility and actual treatment with appropriate statin therapy. Characteristics of patients appropriately and not appropriately treated were compared with chi-square testing and predictors for receiving appropriate statin therapy were determined with logistic regression. Results: A total of 221/300 study subjects were statin-eligible. Fewer statin-eligible PLWH were receiving the correct statin intensity for their risk benefit group versus the uninfected control group (30.2% vs 67.0%, p < 0.001). In the multivariable logistic regression analysis, PLWH were significantly less likely to receive appropriate statin therapy, while those with polypharmacy were more likely to receive appropriate statin therapy. Conclusion: Our study reveals that PLWH may be at a disadvantage in receiving appropriate statin therapy for ASCVD risk reduction. This is important given the heightened risk for ASCVD in this population, and strategies that address this gap in care should be explored.

Comprehensive medication management (CMM) provided by a clinical pharmacist can improve the quality of care and reduce health care costs through the optimization of medication use and a significant reduction in medication‐related problems. As demonstrated by multiple research studies and detailed in published use cases, CMM should be an essential practice for improving population health. This narrative review discusses the limitations of the current evidence and recommends structure, process, and outcome measures to ensure that the key elements of CMM that drive the observed benefits are implemented with fidelity to address the goals of the quadruple aim. The proposed outcome measures are further sub‐classified into economic, clinical, and humanistic categories. Several medication‐related measures are recommended to help define the importance and value of CMM as a key component of population health management.